Warning: The NCBI web site requires JavaScript to function. more...
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.
Breast Cancer Res. 2008;10(5):R74. Epub 2008 Sep 4.
Related citations
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.
Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M; German Breast Group.
Breast Cancer Res. 2008;10(2):R30. Epub 2008 Apr 1.
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY.
BMC Cancer. 2008 Oct 23;8:307.
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
BMC Cancer. 2007 Apr 12;7:63.
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J.
Cancer. 2000 Feb 15;88(4):804-13.
Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al.
Clin Cancer Res. 1995 Feb;1(2):189-98.
p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ.
J Clin Oncol. 1998 Feb;16(2):470-9.
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.
Clin Cancer Res. 2004 Nov 15;10(22):7490-9.
Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L, Baker H, Sinowatz F.
Anticancer Res. 2001 Jan-Feb;21(1B):743-8.
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G.
J Clin Oncol. 2008 Aug 1;26(22):3727-34.
A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.
Xing P, Li J, Jin F.
Med Oncol. 2010 Sep;27(3):926-31. Epub 2009 Sep 23.
Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.
Cancer. 1994 Sep 1;74(5):1575-83.
Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.
J Clin Oncol. 2007 Oct 20;25(30):4772-8. Epub 2007 Sep 17.
Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA.
BMC Cancer. 2010 May 21;10:223.
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
Clin Cancer Res. 2007 Apr 15;13(8):2329-34.
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.
J Clin Oncol. 2008 Mar 20;26(9):1419-26. Epub 2008 Feb 19.
Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM, Albarracin C, Diaz LK, Symmans FW, Edgerton ME, Hwang RF, Sneige N.
Am J Surg Pathol. 2008 Apr;32(4):544-52.
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.
Breast Cancer Res Treat. 2009 Jan;113(2):275-83. Epub 2008 Mar 4.
Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Boracchi P, Fanelli M, Tominaga T.
Int J Oncol. 1998 May;12(5):1117-25.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on